Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice

Virology Journal

Volumn 13, Issue 1, 2016, Pages

  Zhang, Minmin ^a   Ge, Jinying ^a   Li, Xiaofang ^a   Chen, Weiye ^a   Wang, Xijun ^a   Wen, Zhiyuan ^a   Bu, Zhigao ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Glycoprotein; Recombinant Newcastle disease virus; Vaccine; Vesicular stomatitis virus

Indexed keywords

NEUTRALIZING ANTIBODY; VACCINE; VIRUS GLYCOPROTEIN; G PROTEIN, VESICULAR STOMATITIS VIRUS; MEMBRANE PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNIZATION; MOUSE; NEWCASTLE DISEASE VIRUS; NONHUMAN; PATHOGENICITY; PROTEIN EXPRESSION; SUCKLING ANIMAL; VESICULAR STOMATITIS; VESICULOVIRUS; VIRUS LOAD; VIRUS RECOMBINANT; WEIGHT CHANGE; ANIMAL; BIRD DISEASE; CHICK EMBRYO; DISEASE MODEL; GENE EXPRESSION; GENE ORDER; GENE VECTOR; GENETICS; IMMUNOLOGY; MORTALITY; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHICK EMBRYO; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; MEMBRANE GLYCOPROTEINS; MICE; NEWCASTLE DISEASE VIRUS; POULTRY DISEASES; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84977557539     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-016-0481-y     Document Type: Article

References (44)

1. Letchworth GJ, Rodriguez LL, Del Cbarrera J. Vesicular stomatitis. Vet J. 1999;157:239-60.
2. McCluskey BJ, Hurd HS, Mumford EL. Review of the 1997 outbreak of vesicular stomatitis in the western United States. J Am Vet Med Assoc. 1999;215:1259-62.
3. Walton TE, Webb PA, Kramer WL, Smith GC, Davis T, Holbrook FR, et al. Epizootic vesicular stomatitis in Colorado: epidemiologic and entomologic studies. Am J Trop Med Hyg. 1982;1987(36):166-76.
4. Mead DG, Ramberg FB, Besselsen DG, Mare CJ. Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. Science. 2000;287:485-7.
5. Mortimer Jr EA. Immunization against infectious disease. Science. 1978;200:902-7.
6. Brink AJ, Richards GA. Use of vaccines as a key antimicrobial stewardship strategy. S Afr Med J. 2015;105:7409.
7. de la Fuente J, Contreras M. Tick vaccines: current status and future directions. Expert Rev Vaccines. 2015;1-10.
8. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13:521-31.
9. Chen H, Bu Z. Development and application of avian influenza vaccines in China. Curr Top Microbiol Immunol. 2009;333:153-62.
10. OIE Terrestrial Manual. Vesicular stomatitis chapter 2.01.19, 2015.
11. House JA, House C, Dubourget P, Lombard M. Protective immunity in cattle vaccinated with a commercial scale, inactivated, bivalent vesicular stomatitis vaccine. Vaccine. 2003;21:1932-7.
12. Roche S, Albertini AA, Lepault J, Bressanelli S, Gaudin Y. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell Mol Life Sci. 2008;65:1716-28.
13. Freer G, Burkhart C, Ciernik I, Bachmann MF, Hengartner H, Zinkernagel RM. Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen. J Virol. 1994;68:3650-5.
14. Kelley JM, Emerson SU, Wagner RR. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol. 1972;10:1231-5.
15. Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985;227:433-5.
16. Cantlon JD, Gordy PW, Bowen RA. Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis. Vaccine. 2000;18:2368-74.
17. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001;75:11868-73.
18. Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther. 2008;10:46-55.
19. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. Nonsegmented negative-strand viruses as vaccine vectors. J Virol. 2006;80:10293-306.
20. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 2010;84:1489-503.
21. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine. 2010;29:17-25.
22. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol. 2007;81:150-8.
23. Ge J, Wang X, Tao L, Wen Z, Feng N, Yang S, et al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol. 2011;85:8241-52.
24. Khattar SK, Collins PL, Samal SK. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010;28:3159-70.
25. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 2010;28:4394-401.
26. Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, et al. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology. 2012;432:327-35.
27. Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci U S A. 2006;103:8197-202.
28. Goff PH, Krammer F, Hai R, Seibert CW, Margine I, Garcia-Sastre A, et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol. 2013;87:8235-40.
29. Huang Z, Elankumaran S, Yunus AS, Samal SK. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol. 2004;78:10054-63.
30. Ge J, Wang X, Tian M, Gao Y, Wen Z, Yu G, et al. Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks. Vaccine. 2015;33:2457-62.
31. Ge J, Wang X, Tian M, Wen Z, Feng Q, Qi X, et al. Novel in-ovo chimeric recombinant Newcastle disease vaccine protects against both Newcastle disease and infectious bursal disease. Vaccine. 2014;32:1514-21.
32. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2011 Office International des Epizooties, Paris. 2011.
33. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med. 1987;165:64-9.
34. Buijs PR, Verhagen JH, van Eijck CH, van den Hoogen BG. Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother. 2015;11:1573-84.
35. Nakaya Y, Nakaya T, Park MS, Cros J, Imanishi J, Palese P, et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol. 2004;78:9366-75.
36. Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther. 2009;17:697-706.
37. Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS. Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol. 2008;82:9273-7.
38. Flanagan EB, Ball LA, Wertz GW. Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J Virol. 2000;74:7895-902.
39. Markine-Goriaynoff D, Coutelier JP. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J Virol. 2002;76:432-5.
40. Markine-Goriaynoff D, van der Logt JT, Truyens C, Nguyen TD, Heessen FW, Bigaignon G, et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol. 2000;12:223-30.
41. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol. 2003;170:3621-30.
42. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41-51.
43. OIE manual. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2011. Office International des Epizooties: Paris; 2011.
44. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27:493-7.